Biomarkets on the move. January 2013

Biomarkets on the move. January 2013

- Celsion Phase III HEAT study fails.
- FDA to hold a public hearing on ALS on Feb 25.
- Genzyme/ISIS’ Kinamro to be priced at $176,000/year.
- Pharmaxis’ Bronchitol gets negative vote from FDA advisory committee.
- VC Edmond de Rothschild to raise $500 M over four years.
- Antibody company KaloBios preparing for IPO.
- Stemline jumps 18% on its first day of trading.

[Read more...]